PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23538902-0	2013	Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma.	XL 888	80-85	NRAS proto-oncogene, GTPase	Homo sapiens	109-113	
23538902-1	2013	The HSP90 inhibitor XL888 is effective at reversing BRAF inhibitor resistance in melanoma, including that mediated through acquired NRAS mutations.	XL 888	20-25	NRAS proto-oncogene, GTPase	Homo sapiens	132-136	
23538902-2	2013	The present study has investigated the mechanism of action of XL888 in NRAS-mutant melanoma.	XL 888	62-67	NRAS proto-oncogene, GTPase	Homo sapiens	71-75	
23538902-7	2013	In an animal xenograft model of NRAS-mutant melanoma, XL888 treatment led to reduced tumor growth and apoptosis induction.	XL 888	54-59	NRAS proto-oncogene, GTPase	Homo sapiens	32-36